REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (PPBT) ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies ...
A flagship multidisciplinary biotechnology congress organised by the European Federation of Biotechnology. Over five days in ...
Abstracts related to the EACR meeting will be published online following the presentation. For more information, please visit the EACR 2025 website. About Purple Biotech Purple Biotech Ltd. is a ...
First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ...
PanGIA Biotech, a company advancing urine-based, AI-driven diagnostics for early cancer detection, today announced that an abstract co-authored by researchers from PanGIA Biotech, Entopsis Inc., and ...
Stable disease was observed in three out of seven heavily pretreated patients No dose-limiting toxicities or unexpected toxicities were observed HEIDELBERG, Germany, July 31, 2023 (GLOBE NEWSWIRE) -- ...
MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract about the ...
Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemias ...
Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback